<\/p>\nThe numerous data on the use of loratadine in pregnant women (more than 1,000 cases analyzed) indicate that there is no effect of the drug on the occurrence of malformations or fetal and neonatal toxicity of loratadine.<\/p>\n
<\/p>\n
Round, flat-cylindrical tablets of white or almost white color with a score line.<\/p>\n
Loratadine is quickly and well absorbed in the gastrointestinal tract. The time to peak concentration (TMax<\/sub> ) of loratadine in plasma is 1-1.5 hours and that of its active metabolite desloratadine is 1.5-3.7 hours. Ingestion of food prolongs the time to peak concentration (TMax<\/sub> ) of loratadine and desloratadine by about 1 hour, but does not affect the effectiveness of the drug. The maximum concentration (CMax<\/sub> ) of loratadine and desloratadine is not dependent on food intake. In patients with chronic kidney disease, the maximum concentration is (CMax<\/sub> and the area under the concentration-time curve (AUC) of loratadine and its active metabolite are increased compared to patients with normal renal function. The elimination half-lives of loratadine and its active metabolite do not differ from those in healthy patients. In patients with alcohol-related liver dysfunction, CMax<\/sub> and AUC of loratadine increased 2-fold compared to these values in patients with normal liver function, while the pharmacokinetics of the active metabolite were not significantly changed.<\/p>\n Loratadine is highly bound (97-99 %) and its active metabolite moderately bound (73-76 %) to plasma proteins.<\/p>\n Loratadine is metabolized to desloratadine via the cytochrome P system 450<\/sub> 3A4 system and to a lesser extent via cytochrome P 450<\/sub> 2D6. It is excreted via the kidneys (approximately 40 % of the ingested dose) and the intestine (approximately 42 % of the ingested dose) within 10 days, mainly in the form of conjugated metabolites. Approximately 27 % of an orally administered dose is excreted by the kidneys within 24 hours of administration. Less than 1 % of the active substance is excreted unchanged by the kidneys within 24 hours of administration.<\/p>\n The active ingredient of loratadine is a tricyclic compound with pronounced antihistamine effects as a selective blocker of peripheral H1<\/sub>-Histamine receptors. It shows a quick and long-lasting anti-allergic effect. Onset of action occurs within 30 minutes after oral administration of loratadine. The antihistamine effect peaks 8-12 hours after the onset of action and lasts for more than 24 hours.<\/p>\n Loratadine does not cross the blood-brain barrier and has no effects on the central nervous system. It has no clinically relevant anticholinergic or sedative effects, that is, it does not cause drowsiness and does not affect the speed of psychomotor reactions when used in the recommended doses. Administration of loratadine does not result in prolongation of the QT interval on electrocardiogram (ECG).<\/p>\n No clinically significant changes in vital signs, physical examination, laboratory values or electrocardiography were observed during long-term treatment.<\/p>\n Loratadine does not show significant selectivity for H2<\/sub>-Histamine receptors. It does not inhibit the reuptake of norepinephrine and has almost no effect on the cardiovascular system or pacemaker function.<\/p>\n It is known that infections are the most common reason why women visit the gynecologist. Pathogenic infections are caused by both opportunistic flora, the so-called 'normal' genital microflora, and pathogenic microorganisms.<\/p>\n Miramistin\u00ae has been used successfully in obstetrics and gynecology for many years. The main advantage of this drug is its impressive spectrum of action. Miramistin\u00ae is active against a broad spectrum of bacteria and fungi, including those resistant to other antimicrobials, as well as some difficult viruses. 1,2 Miramistin\u00ae in solution form is also widely known as a prophylactic against sexually transmitted infections. 1<\/p>\n The product is now available not only in the familiar solution form, but also as a vaginal suppository. The pharmacological properties of these dosage forms are similar, but Miramistin\u00ae in suppository form was developed specifically for use in gynecology.<\/p>\n Vaginal suppositories for the prevention and treatment of inflammatory diseases in gynecology.<\/p>\n The special nozzle is suitable for use in gynecology for the prevention and treatment of infections, inflammatory gynecological diseases, postpartum injuries, etc.<\/p>\n Miramistin\u00ae is used to prevent and treat the following conditions: Please note that all communications regarding the quality\/safety of medicines received by INFAMED LLC via email, telephone calls or written communications are subject to mandatory processing, with further measures to protect these data in accordance with the requirements of the legislation of the Russian Federation about personal data.<\/p>\n Sending a message to INFAMED LLC implies and confirms your consent to processing (collection, registration, systematization, acquisition, storage, clarification (updating, modification), extraction, use, transfer (provision, access), anonymization, blocking, deletion and destruction ) of your personal data by INFAMED LLC.<\/p>\n Processing is carried out to meet the requirements established by the legislation of the Russian Federation in the field of pharmacovigilance in accordance with the Personal Data Processing and Protection Policy published on the Website.<\/p>\n This consent is valid from the date of its transmission to INFAMED LLC until the date of its revocation, which must be sent in writing to the following address: 142700, Moscow Region, Leninsky District, Vidnoye, Territory of JSC VZ GIAP Industrial Zone, Building 473, Floor 2, Room 9.<\/p>","protected":false},"excerpt":{"rendered":" Die zahlreichen Daten \u00fcber die Anwendung von Loratadin bei Schwangeren (mehr als 1.000 analysierte F\u00e4lle) deuten darauf hin, dass es keine Auswirkungen des Arzneimittels auf das Auftreten von Fehlbildungen oder feto- und neonataler Toxizit\u00e4t von Loratadin gibt. Beschreibung der Darreichungsformen des Arzneimittels Runde, flach-zylindrische Tabletten von wei\u00dfer oder fast wei\u00dfer Farbe mit einer Bruchrille. Loratadin […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"crb-meta-links":"","crb-meta-show":"","crb-meta-show-edited":"","crb-meta-use-manual":"","footnotes":""},"categories":[3],"tags":[],"class_list":["post-3966","post","type-post","status-publish","format-standard","","category-artikel"],"yoast_head":"pharmacodynamics<\/h2>\n
gynecology<\/h2>\n
<\/p>\nvaginal suppositories<\/h5>\n
<\/p>\nWith gynecological nozzle.<\/h5>\n
<\/p>\n
\u2013 Infectious and inflammatory diseases of the female genital organs: vulvovaginitis, including candidiasis (thrush), bacterial vaginosis; 1.2
\u2013 Prevention of postpartum wound and vaginal abscesses; 1.2
\u2013 Postpartum infections. 1.2<\/p>\nConsent to the processing of personal data<\/h3>\n